Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Q1 Biopharma Venture Capital Dips From All-Time High, But Numbers Still Impress

Executive Summary

Private Company Edition: Biotech companies raised $3.9bn, down from $4.6bn in the first quarter of 2019 – a record-breaking year in the US – but dollars per deal stayed above $20m for a second year. Also, Fusion has April's second $100m-plus VC financing with a $105m Series B.

Advertisement

Related Content

Finance Watch: Arteaus Comes Full Circle As Investors Monetize Emgality Royalties
Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases
Finance Watch: Scripps Research Models A New Way To Fund Translation
Finance Watch: 5AM, Longevity Close Funds, New Incubators Launch To Support Early-Stage Companies
Finance Watch: Former Juno Execs Launch Sana With Allogeneic Cell Therapy Platform
Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year
Finance Watch: Genocea, Mateon Shift Strategies, Cut Jobs To Preserve Cash
Venture Funding Deals: New Cash For Delinia, Peloton, Fortis & Others

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125033

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel